Illumina next-generation sequencing (NGS) and microarray technologies represent the gold standard in quality worldwide—and account for ~90% of the world’s sequencing data.* Innovative, intuitive, and completely integrated, our sample-to-data solutions empower your lab to keep ahead of the curve in the rapidly evolving genomics revolution. So you’ll be better able to perform the world-class research you strive for—with the goal of uncovering new insights into the biology of cancer that can lead to meaningful advances in personalized medicine.
Our comprehensive product offerings support multiple cancer research applications, including studies of DNA, RNA, epigenetics, and more. Our range of sequencers can be scaled to meet your needs—from powerful, yet personal, benchtop models to versatile, high-throughput systems. With intuitive data analysis and management capabilities and unsurpassed customer support, we can deliver the answers you seek—quickly, accurately, and cost-effectively.
Explore genomics-based approaches to investigating cancer using NGS and microarrays.
TruSight Tumor 170 accurately identifies diffuse glioma genetic markers, supporting use in tumor characterization for clinical research studies.Read Interview
RNA-Seq and HLA typing are increasing the power and efficiency of a target discovery platform.Read Interview
Researchers use targeted RNA sequencing to understand the role of fusion genes in pediatric leukemia.Read Interview
Targeted DNA and RNA research panel investigating 52 genes with known relevance to solid tumors.Learn More
Flexible desktop sequencing system that supports various applications, from targeted panels to whole-genome sequencing.Learn More
*Data on file based on a 2013 study.